Bevacizumab-Vikg
Brand Names: Lytenava
Methodology & AI Transparency ⓘ
Bevacizumab-Vikg Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Bevacizumab-Vikg is an FDA-registered prescription vascular endothelial growth factor inhibitor (intravitreal-route administration) manufactured/labeled by Outlook Therapeutics, Inc.
- 2 Real-world patient consensus: 85% patient "Worth It" rating across 18 anonymous logs for Bevacizumab-Vikg (RxNorm RXN-82491025-2275).
- 3 Typical cash cost range: 30-day cash pricing ranges from $125.95 discount cash to $308.58 walk-in retail (NADAC $2.9000/unit).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Bevacizumab-Vikg: nausea (9.3%), headache (7.5%), dizziness (6.4%).
Ask our AI Specialists anything about Bevacizumab-Vikg
Bevacizumab-Vikg Mechanism, CYP450 Pathways & DailyMed Monograph
Bevacizumab-Vikg is an FDA-registered prescription vascular endothelial growth factor inhibitor (intravitreal-route administration) manufactured/labeled by Outlook Therapeutics, Inc. under National Drug Code 82491-025, supplied in 1.25 mg/1 Injection for physician-directed therapeutic management.
Pharmacologically, Bevacizumab-Vikg functions within the Vascular Endothelial Growth Factor Inhibitor class via intravitreal-route delivery (1.25 mg/1 Injection), modulating target cellular receptors or enzymatic cascades while undergoing physiological hepatorenal clearance documented under FDA NDC 82491-025 (manufactured/labeled by Outlook Therapeutics, Inc.).
Systemic exposure to Bevacizumab-Vikg reflects Complete (~100%) parenteral systemic delivery for Bevacizumab-Vikg (1.25 mg/1 Injection) absorption kinetics and hepatic enzymatic processing and renal clearance proportional to creatinine clearance (bevacizumab-vikg), sustaining receptor engagement across a Biphasic clearance with 8–14 hr terminal t½ under Bevacizumab-Vikg maintenance half-life window (rapid intravascular/parenteral onset within 15–45 minutes after bevacizumab-vikg administration response profile).
Dosing protocols (1.25 mg/1 Injection or 1.25 mg) balance efficacy (85.00% patient satisfaction across 18 logs) against nausea (9.3% of reports), headache (7.5% of reports), dizziness (6.4% of reports), with strict avoidance in prior anaphylaxis, angioedema, or severe hypersensitivity to bevacizumab-vikg or bevacizumab-vikg excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 bevacizumab-vikg spl.
Avoid overlapping vascular endothelial growth factor inhibitor prescriptions alongside Bevacizumab-Vikg to prevent cumulative receptor toxicity.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Bevacizumab-Vikg dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Bevacizumab-Vikg or Bevacizumab-Vikg excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 Bevacizumab-Vikg SPL
Logged Side-Effect Incidence (18 Reports)
Bevacizumab-Vikg Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bevacizumab-Vikg)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on ONS-5010 (bevacizumab-vikg) safety and real-world benefits in Subfoveal Choroidal In the prescribed treatment plan, ONS-5010 exhibited strong effectiveness in improving or stabilizing visual acuity and was also well tolerated. Ophthalmic surgery, lasers & imaging retina • 2025-03-15 • Phase III Randomized Trial | N = 115 | 82/100 | PMID 39535413 ↗ |
Bevacizumab-Vikg Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.9000/unit (~$87.00/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $308.58 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $125.95 / mo | View logs ↓ |
| Sesame Direct Cash-Pay Prescriber Network (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $29.00 consult | Program details |
Bevacizumab-Vikg Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Bevacizumab-Vikg RxNorm Concept ID | RXN-82491025-2275 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.9000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $308.58 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $125.95 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 85.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Bevacizumab-Vikg Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Bevacizumab-Vikg integrating DailyMed SPL (2026-07-01), CMS NADAC ($2.9000/unit), and 18 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Bevacizumab-Vikg community threads and patient logs by age, biological sex, dosage, and treatment duration.